What went wrong in Connect Biopharma’s Seabreeze STAT asthma trial?
CNTB falls 32% after rademikibart misses its asthma primary endpoint despite a 66% treatment-failure reduction and significant FEV1 gain.
Pharma & Biotech
Pharma & Biotech
Connect Biopharma advances rademikibart data as global competition grows in eczema biologics
Rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what the trial could mean for IL-4 receptor biologics and global dermatology drug competition.